• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

Improving brain health: the future in mind

MENUMENU
  • About
    • About
    • Our People
    • Timeline of our key achievements since 2017
    • Core facilities
    • Management and partners
    • Work with us
    • Contact
  • Departments
    • NIHR Oxford Cognitive Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Overview of Research Themes
    • Adult Mental Health
    • Older Adults and Dementia
    • Precision Psychological Therapies
    • Clinical Research Infrastructure and Experimental Medicine
    • Informatics and Digital Health
    • Neuroimaging and Cognitive Neuroscience
    • Patient and Public Involvement
    • Training theme
    • Theme Leads
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Blog
    • Training & Events
    • Psychiatry department seminars
  • Training Hub
  • Patients & Public
    • About Patient and Public Involvement
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
You are here: Home / Departments / Welcome to the Oxford Precision Psychiatry Lab (OxPPL) / International projects

Oxford Precision Psychiatry Lab

International projects


The Oxford Precision Psychiatry Lab (OxPPL) is currently working on the following projects.

  • PAIDEIA
  • PETRUSHKA
  • GRISELDA
  • MARTHA
  • NATALIA
  • SUSANA

PAIDEIA

What does PAIDEIA stand for?

Personalised AI vs Designed by Experts Individualised Approach.

What is PAIDEIA?

PAIDEIA is a trial aiming at improving and protecting mental wellbeing during and after COVID-19.
We aim to compare two ways of individualising evidence-based interventions, the AI and the designed by experts approaches. Physical exercise and mindfulness are the two evidence-based interventions offered within the PAIDEIA study in a personalised approached tailored to individual needs, to aid the mental health and general wellbeing of people.

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Gayathri Delanerolle, Department of Psychiatry, University of Oxford, Oxford, UK
Nyla Haque, Department of Psychiatry, University of Oxford, Oxford, UK
Edoardo G Ostinelli, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Jack Quaddy, Department of Psychiatry, University of Oxford, Oxford, UK
Katherine Stevens, Department of Psychiatry, University of Oxford, Oxford, UK
Maxime Taquet, Department of Psychiatry, University of Oxford, Oxford, UK
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK
John Torous, Department of Psychiatry, Harvard Medical School, Boston


PETRUSHKA

What does PETRUSHKA stand for?

Personalise antidEpressant TReatment for Unipolar depreSsion combining individual cHoices, risKs and big datA.

What is PETRUSHKA?

PETRUSHKA is a project funded by the National Institute of Health Research (NIHR), aimed at developing and subsequently testing a precision medicine approach to the acute pharmacological treatment of major depressive disorder in adults, which can be used in everyday clinical settings.

We will jointly synthesise data from patients with depressive disorder, obtained from diverse datasets, including randomised, observational, real-world studies. Results from this analysis will subsequently inform a web-based platform, which will allow shared decision-making at the individual-patient level during the routine consultation between clinicians and patient.

Protocol

Tomlinson et al., Personalise antidEpressant TReatment for Unipolar depreSsion combining individual cHoices, risKs and big datA (PETRUSHKA): Rationale and Protocol. Evidence-Based Mental Health 2020;23:52-56.

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Franco De Crescenzo, Department of Psychiatry, University of Oxford, Oxford, UK
Gayathri Delanerolle, Department of Psychiatry, University of Oxford, Oxford, UK
Orestis Efthimiou, Institute of Social and Preventive Medicine, Bern, Switzerland
Toshi A Furukawa, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Nyla Haque, Department of Psychiatry, University of Oxford, Oxford, UK
Zhenpeng Li, Department of Psychiatry, University of Oxford, Oxford, UK
Qiang Liu, Department of Psychiatry, University of Oxford, Oxford, UK
Huseyin Naci, Department of Health Policy, The London School of Economics and Political Science, London, UK
Alejo Nevado-Olgado, Department of Psychiatry, University of Oxford, Oxford, UK
Bessie O’Dell, Department of Psychiatry, University of Oxford, Oxford, UK
Edoardo G Ostinelli, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Georgia Salanti, Institute of Social and Preventive Medicine, Bern, Switzerland
Ilina Singh, Department of Psychiatry, University of Oxford, Oxford, UK
Katherine Stevens, Department of Psychiatry, University of Oxford, Oxford, UK
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK


GRISELDA

What does GRISELDA stand for?

Group of Researchers Investigating Specific Efficacy of individuaL Drugs for Acute depression.

What is GRISELDA?

A project (network meta-analysis) comparing the efficacy and acceptability of 21 antidepressants used in the acute treatment of depression in adults.

Publication

Cipriani et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Lauren Atkinson, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Centre for Human Brain Activity, Department of Psychiatry, Warneford Hospital, Oxford, UK
Anna Chaimani, Institute of Social and Preventive Medicine, Bern, Switzerland
Matthias Eggar Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Toshi A Furukawa, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
John Geddes Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Yu Hayasaka, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan
Julian Huggins School of Social and Community Medicine, University of Bristol, Bristol, UK
Hissei Imai, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan
John Ioannidis, Department of Medicine, Department of Health Research and Policy, Department of Biomedical Data Science, and Department of Statistics, Stanford University, Stanford, CA, USA; Meta-Research Innovation Center at Stanford, Stanford University, Stanford, CA, USA
Stefan Leucht Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany
Yusuke Ogawa Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan
Henricus Ruhe Department of Psychiatry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Georgia Salanti, Institute of Social and Preventive Medicine, Bern, Switzerland
Kiyomi Shinohara, Department of Health Promotion and Human Behavior Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan
Aran Tajika, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan
Nozomi Takeshima, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan
Erick Turner Behavioral Health and Neurosciences Division, VA Portland Health Care System, Portland, OR, USA; Department of Psychiatry and Department Pharmacology, Oregon Health & Science University, Portland, OR, USA

GRISELDA Update

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Katharine Boaden, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Orestis Efthimiou, Institute of Social and Preventive Medicine, Bern, Switzerland
Toshi A Furukawa, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK


MARTHA

What does MARTHA stand for?

Meta-Analysis of Relative Tolerability and Harms of Antidepressant

What is MARTHA?

The MARTHA project is a network meta-analysis and standard meta-analysis comparing the tolerability of 21 antidepressants used in the acute treatment of depression in adults. This project examines all the individual adverse events (side effects) of the 21 antidepressants including the frequently occurring and rare adverse events.

Protocol

Tomlinson et al,. Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. Evid Based Ment Health. 2019 May;22(2):61-66. doi: 10.1136/ebmental-2019-300087. Epub 2019 Apr 17.

Prospero

https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=128141

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Katharine Boaden, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Astrid Chevance, Paris Descartes University, Paris, France; METHODS Team, Center for Research in Epidemiology and Statistics, Sorbo
Orestis Efthimiou, Institute of Social and Preventive Medicine, Bern, Switzerland
Toshi A Furukawa, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Shino Kikuchi, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Sanae Kishimoto, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Sarah Mather, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Emma New, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Hissei Imai, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Yusuke Ogawa, Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Aran Tajika, Department of Psychiatry, Kyoto University Hospital, Kyoto, Japan
Georgia Salanti, Institute of Social and Preventive Medicine, Bern, Switzerland
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK


NATALIA

What does NATALIA stand for?

Network meta-Analysis Targeting Antidepressant Long term effects In Adults with depression

What is NATALIA?

The NATALIA project follows on from GRISELDA, which focused on the acute treatment of depression. It is important that we complete the story and investigate the longer-term effects of antidepressants in adults. A project using a pairwise meta-analysis and a network meta-analysis (NMA) to examine the relative efficacy, tolerability and acceptability of antidepressants in the long-term treatment of major depression.

Protocol

Shinohara et al., Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and network meta-analysis. BMJ Open. 2019 May 19;9(5):e027574. doi: 10.1136/bmjopen-2018-027574.

Team

Andrea Cipriani Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Katharine Boaden, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Orestis Efthimiou, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Toshi A Furukawa, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
John Geddes, Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Andrew A Nierenberg, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, US
Edoardo G Ostinelli, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Henricus G Ruhe, Department of Psychiatry, Radboud University, Nijmegen, the Netherlands
Kiyomi Shinohara, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK


SUSANA

What does SUSANA stand for?

Survey to Understand the Side effects of ANtidepressants in Adults

What is SUSANA?

The SUSANA survey is a designed with the intention to collect data from thousands of patients and prescribers, SUSANA will enable us to identify and rank the most common side effects of antidepressants, based on how troublesome and impairing they can be for patients in the real world Read more about SUSANA here.

Protocol

Tomlinson et al., Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. Evid Based Ment Health. 2019 May;22(2):61-66. doi: 10.1136/ebmental-2019-300087. Epub 2019 Apr 17.

Team

Andrea Cipriani, Department of Psychiatry, University of Oxford, Oxford, UK: Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford
Astrid Chevance, Paris Descartes University, Paris, France; METHODS Team, Center for Research in Epidemiology and Statistics, Sorbo
Orestis Efthimiou, Institute of Social and Preventive Medicine, Bern, Switzerland
Toshi A Furukawa, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan
Anneka Tomlinson, Department of Psychiatry, University of Oxford, Oxford, UK

Back to top

Primary Sidebar

Oxford Precision Psychiatry Lab

  • Welcome
  • COVID-19 & clinical management of mental health issues
    • Media – articles and videos
  • International projects
  • Systematic reviews and meta-analysis
  • Patient Involvement and Ethics
  • Publications
  • OxPPL Team
  • OxPPL Events

Tweets by Oxford Precision Psychiatry Lab

Tweets by OxfordPPL
Follow @OxfordPPL

Footer

Follow us

  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford. We are part of the Oxford Academic Health Science Centre.

Oxford Academic Health Science Centre
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact

© 2022 NIHR Oxford Health Biomedical Research Centre · Log in

Cookies

This site uses cookies: See our privacy policy